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MicroAbstract 
We reported the first case of Mtillerian adenosarcoma arising in the urinary bladder with 
extensive clinicopathologic, immunohistochemical, and molecular analyses. Given the 
tendency of low-grade mtillerian adenosarcomas to recur and/or develop stromal 
overgrowth, discerning this diagnostic entity from benign extra-uterine processes (such as 
endometriosis) has important diagnostic and clinical implications. 
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Abstract 
Mtillerian adenosarcoma is a biphasic neoplasm most commonly of the uterus and less 
frequently of the ovary. It has been rarely described to occur in other sites such as 
peritoneum and liver. In this study, we report the clinicopathologic, 
immunohistochemical and molecular features of a primary mtillerian adenosarcoma of 
the urinary bladder in a 62-year-old woman. To our knowledge, this is the first report of 
mtillerian adenosarcoma primary to the urinary bladder in the literature. Light 
microscopy showed a biphasic epithelial and stromal tumor with benign-appearing glands 
surrounded by endometrial-type stroma that is densely cellular with increased mitotic 
figures. The stroma surrounding the glands is more cellular than the intervening areas, 
which are more loose and edematous. Immunohistochemistry profile included positive 
staining for Pax2/8 within the glands, for CD 10 and WT-1 within the spindled stroma, 
and for estrogen and progesterone receptors in both. Staining for desmin, GATA3, p63, 
and human papilloma virus (HPV) is negative. Molecular analyses identified mutations in 
AKTl El 7K, FLT3 D835N, KRAS G 12D and HRAS G 12S. These novel molecular 
aberrations have yet to be reported in the medical literature. X chromosome inactivation 
analysis revealed a clonal pattern in the stromal component and a non-clonal pattern in 
the epithelial component. Currently, the patient is disease/recurrence-free after regular 
follow-up of approximately 84 months. This case represents the first reported diagnosis 
of mtillerian adenosarcoma arising in the urinary bladder with extensive 
clinicopathologic, immunohistochemical, and molecular analyses. 
(Word counts:239) 
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Introduction 
Mtillerian (mesodermal) adenosarcoma is a distinctive type of mixed epithelial 
and mesenchymal tumor of the female genital tract that was first described in 1974.1 
These tumors are most often found in the uterus. 1-3 The ovary is the most common 
extrauterine site.4 These tumors have also been found in the pelvis,5-7 vagina, 8 and liver.9 
The epithelial component is typically composed of benign-appearing glands that can be 
dilated or slit-like. The epithelium is most often endometrioid, but can also be mucinous 
(endocervical), ciliated, squamous, or serous.2 Occasionally, tumors with an atypical 
glandular component have been described.2 The mesenchymal component usually 
consists of a low-grade malignant stroma may exhibit overgrowth, sometimes significant, 
compared to the epithelial component. Tumors with sarcomatous overgrowth and 
aggressive clinical course have been described. 1 There are 13 reported cases of mtillerian 
adenosarcoma occurring in patients being treated with Tamoxifen therapy. 10-15 
We report a case of mtillerian adenosarcoma of the urinary bladder occurring in a 
patient with long-standing history of endometriosis. In addition to an extensive 
immunohistochemical panel, we performed next generation sequencing, virtual karyotype 
analysis, and X-chromosome inactivation analysis. To our knowledge, this is the first 
case of mtillerian adenosarcoma primary to the urinary bladder with concurrent 
histopathologic, immunohistochemical and molecular analyses, including novel 
molecular aberrations yet to be reported in the literature. 
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Materials and Methods 
Clinical Presentation 
A 62 year-old woman presented for urological evaluation due to gross hematuria. 
Her previous surgical history included a hysterectomy at an outside institution 15 years 
prior. Pathologic findings in the uterus from that procedure were not known. Cystoscopy 
had been performed 12 years prior for hematuria, which showed a mass at the base of the 
urinary bladder clinically described as an endometrioma. This was reported to be 
compatible with known history of endometriosis in conjunction with a urinary tract 
infection at that time. Pathology from this prior resection was not available for review. 
Due to recurrent hematuria, cystoscopy and subsequent transurethral resection of 
a 2 - 3 cm bladder mass located adjacent to the right ureteral orifice were performed, 
clinically believed to represent a recurrent endometrioma. Pathologic review of the 
specimen yielded a diagnosis of endometrial-type tissue with atypical spindle cell 
proliferation. Given the suspicion for a low-grade mtillerian adenosarcoma and the 
inability to completely resect the lesion transurethrally, a partial cystectomy was 
performed. Intraoperatively, the lesion appeared to extend into the bladder wall and the 
right distal ureter. 
Pathologic evaluation of the submitted specimens identified a urinary bladder-
based tumor consisting of benign endometrial glands surrounded by highly cellular and 
atypical spindle cells consistent with a mtillerian (mesodermal) adenosarcoma. 
Background endometriosis was also identified. Surgical margins were negative and the 
lesion was considered completely excised. Lymph nodes were not sampled. 
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Since the repair, the patient has had no additional complications from the 
procedure and is disease-free to date after close observation and regularly scheduled 
follow-up (approximately 84 months). 
Immunohistochemistry and Molecular Analyses 
A search through our institution's surgical pathology files identified the prior 
transurethral resection of the urinary bladder and subsequent partial cystectomy. 
Hematoxylin and eosin as well as immunohistochemical stains (with appropriate 
controls) from both cases were obtained for review. Paraffin blocks were obtained for 
molecular studies. This review was approved by our institutional review board (IRB). 
Antibodies directed against beta-catenin (M3539, dilution 1:60, Dako Corp. 
Carpentaria, CA), CA-125 (CMA743, Cell Marque, Darmstadt, Germany), CDlO (IR 
648, Dako Corp,.), CK7 (IR 619 Dako Corp.), CK20 (IR 777, Dako Corp.), desmin (IR 
606; Dako Corp.), ERG (IR 659 Dako Corp.), estrogen receptor (IR 151, Dako Corp.), 
GATA3 (SC 268, dilution 1:50, Santa Cruz Biotechnology, Dallas, TX), HPV (M3528, 
dilution 1:25, Dako Corp.), Ki-67 (IR 626, dilution 1:300, Dako Corp.), p63 (M7247, 
dilution 1 :400, Dako Corp.), Pax-2 (Invitrogen, dilution 1: 100, Thermo Fisher Scientific, 
Waltham, MA), Pax-8 (EP298, Cell Marque), progesterone receptor (IR 068; Dako 
Corp.), smooth muscle actin (1A4; Dako Corp), TTF-1 (IR 056, Dako Corp.), and WT-1 
(IR 055, Dako Corp.) were performed in a Dako Corp. automated instrument. Positive 
and negative controls gave appropriate results for each antibody performed. 
Molecular studies including next generation sequencing (NGS), single nucleotide 
polymorphism array assay and X chromosome inactivation analysis were performed. 
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DNA was obtained from selected formal fixed paraffin embedded (FFPE) tissue 
to obtain nuclei acid extract to perform multiplexed targeted sequencing assays to detect 
for mutations. Regions of viable tumor were selected by an experienced genitourinary 
pathologist (L.C.) on hematoxylin and eosin stained slides and corresponding unstained 
slides were deparaffinized with two washes of xylene, 15 minutes each, and subsequently 
washed twice with absolute ethanol, 10 minutes each, and then air-dried in a fume hood. 
Subsequent protein digestion and DNA extraction were completed. Pre-screening for 
specimen adequacy was performed according to the protocols of TruSeq Amplicon 
Cancer Panel quality control kit for FFPE samples (ACP; Illumina, San Diego, CA). 
Once the sample was deemed adequate, the extracted DNA was analyzed via single-tube 
reaction evaluating 48 different genes targeted by 212 amplicons on the Illumina MiSeq 
system. 
For virtual karyotyping, DNA was obtained from manually microdissected 10 µm 
paraffin sections according to previously described protocol and processed with an FFPE-
optimized protocol based on the GeneChip Mapping 250K Nsp SNP (single nucleotide 
polymorphism) Assay Kits (Affymetrix, Santa Clara, CA) as previously described16-18 . 
X chromosome inactivation analysis was performed using DNA prepared from 
the cystectomy specimen, using methods previously described 19-21 . Analysis utilized a 
highly polymorphic CAG repeat in exon 1 of the human androgen receptor gene on 
chromosome Xpl 1-12. Briefly, the DNA extract was digested with Hhal (New England 
Biolabs Inc., Beverly, MA) and amplified in a polymerase chain reaction mixture 
containing 0.1 µL of a a-32P-labeled deoxyadenosine triphosphate (3000 Ci/mmol/L), 
AR-sense and AR-antisense primers (each at 4 mol/L), 4% dimethyl sulfoxide, MgCb at 
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2.5 mmol/L, all 4 deoxynucleoside triphosphates (each at 300 µmol/L), and 0.5 U of Taq 
DNA polymerase (Perkin-Elmer Cetus, Foster City, CA). The samples were then heated 
to 95°C for 5 minutes and then placed on ice. Electrophoresis was performed using 6.5% 
denaturing polyacrylamide gel at 80W for 3 hours, followed by autoradiography with 
Biomax MS film (Kodak Company, Rochester, NY) for 8 to 18 hours. Control tissue 
yielded an appropriate reaction. 
Results 
Histopathologic Findings 
The partial cystectomy specimen consisted of a portion of urinary bladder, 
anterior vaginal wall, and right ureteral orifice measuring 6.0 x 5.0 x 3.6 cm. A distinct 
mass was not appreciated; however, sectioning revealed a gray-white to red-brown cut 
surface remarkable for fibrosis admixed with areas of softening. These foci connect with 
lobulated and polypoid areas located on the mucosa! surface. 
The tumor was centered in the muscular wall of the urinary bladder, involving the 
adjacent perivesical and peri-ureter soft tissue. The tumor was characterized by benign-
appearing glands lined by predominantly cuboidal cells with variably eosinophilic 
cytoplasm. Mitotic figures and nuclear atypia were essentially being absent (Fig. lA, B). 
Occasionally, glands were lined by flattened and pseudostratified epithelium. The glands 
were surrounded by endometrial-type stroma that was densely cellular with mild nuclear 
atypia and increased mitoses (up to 3 per 10 high-powered fields) [Fig. lC, D]. The 
stroma surrounding the glands was more cellular than the intervening areas which was 
looser, edematous, and somewhat myoid-appearing (Fig. lE). The tumor also makes 
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intraglandular papillary-like projections (lined by bland cuboidal and occasionally 
pseudostratified cells) resembling phyllodes tumor of the breast (Fig. lF). When 
compared to the prior transurethral resection, the stroma in the partial cystectomy 
specimen was more atypical in appearance and indeed possessed features of low-grade 
malignancy. There was also intravascular tumor in thin and thick walled vessels (Fig. 
2A). Heterologous stromal elements and high-grade sarcomatous overgrowth were not 
identified. The uninvolved urinary bladder contained foci of endometriosis. 
The tumor focally extended to cauterized muscularis propria in the main 
specimen, but it was unknown whether this area represented true margin. All additional 
inked and separately submitted margins were negative for tumor. 
Immunohistochemical Findings 
The benign glandular elements stain for Pax-2, Pax-8, and CK7 (focal, patchy) 
[Fig. 3A-B].Staining within the sarcomatous stroma shows positive immunoreactivity for 
CDlO, WT-1, and smooth muscle actin (patchy) [Fig. 3C-E]. CA-125, estrogen receptor, 
progesterone receptor, and beta-catenin (nuclear) were positive in both components (Fig 
F-H). Overall, staining for CK20, desmin, GATA3, HPV, p63, and TTF-1 is negative in 
both components. Staining for ERG and elastin highlights tumor within lymphovascular 
spaces (Fig. 2B). Ki-67 shows a proliferation index of approximately 1 %. 
Mutation Analysis 
Multiplexed targeted sequencing (Next Generation Sequencing, NGS) identified 
the following mutations: HRAS Gl2S, KRAS Gl2D, AKTl El7K, and FLT3 D835N. 
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X chromosome Inactivation Analysis 
X-chromosome inactivation analysis revealed a clonal pattern, i.e. non-random 
pattern of X chromosome inactivation, in the stromal component that is characterized by 
a single androgen receptor band after digestion with Hhal restriction endonuclease. The 
epithelial component revealed a random pattern of X chromosome inactivation (Fig. 4). 
Virtual Karyotyping by Single Nucleotide Polymorphism Array Assay 
The specimen showed discrete chromosomal imbalances in chromosomes 1and3. 
Chromosome 1showeda47.3 Mb region of gain in the long arm: lq(23.3-32.3, 
160285587-209409174/hgl 7). Chromosome 3 showed a 21.4 Mb region ofloss in the 
short arm: 3p(l4.l-22.l, 43012181-64488564/hgl7) [Fig. 4]. 
Discussion 
Primary mtillerian (mesodermal) adenosarcoma of the urinary bladder is an 
exceptionally rare tumor with no prior report of extensive immunohistochemical or 
molecular findings in the literature. In this article, we report the first case of mtillerian 
adenosarcoma of the urinary bladder with extensive morphologic and 
immunophenotypic classification in addition to detection of novel molecular aberrations 
including AKTl, HRAS, FLT3, and KRAS somatic mutations by NGS, imbalances of 
chromosomes 1 and 3, as well as X chromosome inactivation. 
Prior extra-gynecologic tract cases of mtillerian adenosarcoma have been reported 
in the peritoneum, ureter, liver, prostate, testis, and seminal vesicles22-25 . While the 
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etiologies of these rare occurrences of mtillerian adenosarcoma in men have yielded 
several hypotheses of their origin, the extra-uterine/ovarian cases within the female 
population have been almost exclusively associated with endometriosis (or 
mtillerianosis)22. Additionally, the association between mesodermal adenosarcoma and 
tamoxifen therapy is well documented; however, our patient had no reported use of 
tamoxifen10-15 . 
Histopathologically, mtillerian/mesodermal adenosarcoma is a biphasic neoplasm 
consisting of malignant mesenchymal and benign (to mildly atypical) epithelial 
components 1. The epithelial component typically consists of evenly distributed glands 
lined by endometrioid-like epithelium ( cuboidal or columnar cells with occasional 
pseudostratification) that is not overtly malignant. The background mesenchymal stroma 
is variably cellular, with increased cellularity around the benign glands creating a "cuffed 
or collared" appearance4. The stromal cells are mild to moderately atypical with a 
variable amount of increased mitotic figures. The cellular stroma can extend into 
glandular or cystic spaces, in a papillary or polypoid fashion, imparting an appearance 
most analogous to phyllodes tumor of the breast2. These projections are lined by benign 
to mildly atypical epithelial cells. Again, similar to phyllodes tumor of the breast, 
mtillerian adenosarcomas can undergo stromal overgrowth, with rhabdomyomatous 
features, and are classified as adenosarcoma with sarcomatous overgrowth according to 
the WHO Classification of Female Reproductive Organs10' 26 . Adenosarcomas are 
typically positive for CD 10, estrogen (ER) and progesterone receptors (PR) within the 
stromal component as well as Pax-2/8 within the benign epithelial components. In our 
immunohistochemical studies, we additionally identified positive immunoreactivity in the 
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stroma for WT-1, SMA (focal), beta-catenin (focal), and CA-125 (focal). Within the 
benign epithelial component, we identified further positive immunoreactivity for CK7 
(focal), ER, PR, and beta-catenin (nuclear). 
To our knowledge, this is only the third proposed case of mtillerian adenosarcoma 
of the urinary bladder published in peer-reviewed journals27' 28 . The first reported case 
had a very limited description of morphologic features and was postulated to arise out of 
endometriosis in the prevesical fat rather than the urinary bladder27 . Additionally, 
immunohistochemical or molecular studies were not performed27 . The second previously 
reported occurrence was a single case of presumed urinary bladder adenosarcoma in 
2002, but the pathology was never specifically reviewed to confirm the diagnosis28 . 
Limited immunohistochemical findings were described (per report, without review) and 
no molecular studies were performed. Findings in our case are diagnostic of mtillerian 
adenosarcoma by morphologic, immunophenotypic, and molecular findings. The stromal 
features including increased mitotic activity, cellular atypia, and "cuffing" around benign 
glands exceed any benign process. Additionally, the phyllodes-like growth patterns in 
conjunction with our immunophenotypic findings are quite consistent with this diagnosis. 
With no stromal overgrowth identified, a classification of low-grade adenosarcoma was 
most appropriate. 
Few studies have evaluated molecular aberrations seen in primary uterine 
mtillerian adenosarcoma. Cytogenetic and molecular analyses identifying chromosome 
gains/losses and/or complex karyotype involving chromosomes such as 2, 8, 10, 13, 19 
and 21 have been reported. 29' 30 Additionally, somatic mutations of numerous genes 
including MDM2, CDK4, DDIT3, CKDN2A, FGFR2 as well as alterations in the 
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PIK3CA/AKT/PTEN pathway have been identified30-32 . One prior study evaluated 
tumors by DNA flow cytometric analysis and while assessing for DNA ploidy, a subset 
were DNA diploid and all cases had an S-phase fraction <10%33 . 
After an extensive literature search, we have found a significant paucity of 
molecular/cytogenetic studies of extra-uterine mesodermal adenosarcomas. While our 
findings in the AKTl pathway are similar to those previously reported in primary uterine 
adenosarcoma, the mutations of HRAS, KRAS, and FLT3 are unique. It should be noted 
that TruSeq Amplicon-Cancer Panel used to analyze this tumor (by NGS) did evaluate 
for various other previously described mutations and these were not identified in this 
tumor. Our reporting of chromosomal imbalances in chromosome 1 and 3 are the first of 
their kind in mtillerian adenosarcoma. Of note, the 3p loss region did not include the 
VHL gene, but it did include the PBRMl gene. While PBRMl has been reported to be 
mutated in a high percentage of clear cell renal cell carcinoma tumors, we found no prior 
report of this gene being lost or mutated in mtillerian adenosarcomas34. 
The differential diagnosis in a case such as this depends on the presumed site of 
origin for the lesion. Given the localization of the tumor to the urinary bladder wall, 
primary bladder neoplasia, neoplasia arising out of metaplasia, or a metastatic lesion from 
another primary site should be primary considerations. Primary sarcomatous lesions of 
the urinary bladder to consider include leiomyosarcoma and sarcomatoid urothelial 
carcinoma. While leiomyosarcoma is the most common bladder sarcoma, this tumor 
lacked morphologic features typically associated with the diagnosis including interlacing 
fascicles of cigar-shaped nuclei or significant immunoreactivity with desmin, caldesmon, 
or smooth muscle actin35 . A diagnosis of sarcomatoid urothelial carcinoma could be 
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considered; however, the lack of a malignant epithelial component, presence of benign 
glandular morphology, and lack of immunoreactivity with p63, GATA3, or cytokeratin 
(within the sarcomatous component) argued against this diagnosis36• 
Previously reported mass forming lesions of the urinary bladder associated with 
endometriosis, or less commonly mtillerianosis, include mass-forming endometriosis, 
clear cell adenocarcinoma, endometrioid adenocarcinoma, and endometrial stroma 
sarcoma37-39 . Given the stromal cellularity, infiltrative nature, increased mitotic activity, 
and nuclear atypia, features in the stromal component of this lesion far surpassed what is 
expected in a benign endometrioma40. While clear cell or endometrioid adenocarcinoma 
arising out of endometriosis could create a mass-forming lesion with glandular 
morphology, these diagnoses were not a consideration in this case as the lesion lacked a 
malignant epithelial component. Given the stromal predominance of these lesions, low-
grade endometrial stromal sarcoma (ESS) could be a diagnostic consideration. Tian et al 
previously described a case series of 6 ESSs arising out of the urinary bladder39. While 
the immunophenotypic overlap is intriguing, their study only described a single case 
arising out of the urinary bladder (the remainder were remote metastases) and 
furthermore, ESS in their study lacked a benign glandular component39. 
Adenosarcomas have been described to recur in up to 30% of cases; however, 
metastasis is very uncommon and has only been reported in cases of stromal 
overgrowth41 . While the pathology from this patient's remote hysterectomy was unknown 
at the time of her current diagnosis, it is highly unlikely this represents a metastasis from 
a prior uterine, ovarian, or cervical adenosarcoma. Given the location being centered in 
the urinary bladder wall and lack of involvement of the vaginal wall, this tumor does not 
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represent a vaginal primary extending into the urinary bladder. Of note, the patient's prior 
resection of a clinically-assessed endometrioma very well could have been an 
undiagnosed mtillerian adenosarcoma which subsequently recurred. Unfortunately, the 
absence of prior pathology material makes this purely speculative. 
Conclusions 
Overall, extra-uterine mtillerian adenosarcoma of the urinary bladder is 
exceedingly rare. We believe this represents the first study of extra-gynecologic 
mtillerian (mesodermal) adenosarcoma that includes extensive immunophenotypic 
studies and molecular analysis with novel cytogenetic findings including mutations in 
KRAS, HRAS, AKTl, and FLT3. The possibility for endometriosis to form mass-like 
lesions in the urinary bladder is well known. Given the tendency of low-grade mtillerian 
adenosarcomas to recur and/or develop stromal overgrowth, discerning this diagnostic 
entity from benign extra-uterine processes (such as endometriosis) has important 
diagnostic and clinical implications. 
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Clinical practice points: 
• Extra-uterine mtillerian adenosarcoma is rare. We report the clinicopathologic, 
immunohistochemical and molecular features of a primary mtillerian 
adenosarcoma of bladder. 
• Immunohistochemistry profile included positive staining for P AX8 within the 
glands, for CD 10 and WT-1 within the spindled stroma 
• Molecular analyses identified mutations in AKTl El7K, FLT3 D835N, 
KRAS Gl2D and HRAS Gl2S. 
• X chromosome inactivation analysis revealed a clonal pattern in the stromal 
component and a non-clonal pattern in the epithelial component. 
• Given the tendency of low-grade mtillerian adenosarcomas to recur and/or 
develop stromal overgrowth, discerning this diagnostic entity from benign 
extra-uterine processes (such as endometriosis) has important diagnostic and 
clinical implications. 
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Figure Legends 
Figure 1. Primary urinary bladder mtillerian adenosarcoma (hematoxylin and eosin 
staining). A. Benign-appearing glands are lined by predominantly cuboidal cells with 
eosinophilic cytoplasm. B. Low-grade mtillerian adenosarcoma infiltrating into 
perivesical fat. C, D. Densely cellular endometrial-type stroma with mild nuclear atypia 
and increased mitotic figures surrounding benign glands that is often referred to as 
"cuffing" or "collaring". E. Looser, edematous, and somewhat myoid-appearing stroma. 
F. Intraglandular, papillary-like projections resembling phyllodes tumor of the breast. 
Figure 2. Lymphovascular space invasion. The presence of low-grade mtillerian 
adenocarcinoma within the large vessels of the urinary bladder ( H&E stain, A: 4x and C: 
20x magnifications) highlighted by an immunohistochemical stain for ERG (B, 4x and D, 
20x) 
Figure 3. Positive immunohistochemical staining within glandular component. A. Pax8 
and B. CK7. Positive immunohistochemical staining within sarcomatous component. C. 
CDlO D. WT-1 and E. smooth muscle actin. Positive immunohistochemical staining in 
both morphologic components. F. estrogen receptor G. progesterone receptor and H. CA-
125 
Figure 4. X Chromosome inactivation analysis and virtual karyotypes of Mullerian 
Adenosarcoma. A-C. Laser microdissection of mtillerian adenosarcoma of the urinary 
bladder. A, tumor before microdissection; B, tumor after microdissection; and C, laser-
22 
captured tumor cells. D. A clonal pattern in the stromal component that is characterized 
by a single androgen receptor band after digestion with Hhal restriction endonuclease is 
demonstrated in this micrograph. For comparison, the epithelial component revealed a 
random pattern of X chromosome inactivation. E. The uppermost plot represents the 
estimated copy number as a log 2 ratio averaged over 30 SNPs; green bars represent 
heterozygote SNPs; middle bar represents a color-coded Hidden Markov Model (HMM) 
for copy number (yellow, copy number 2; pink, copy number 3; aqua, copy number 1), 
and bottom bar is a color-coded HMM for LOH (yellow, no LOH; blue, LOH). This 
profile shows discrete regions of gain in chromosome lq and loss in chromosome 3p. 
23 
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